AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsTechnology, Industry, AgricultureInformation ScienceNamed GroupsHealth Care
Hepatitis BHepatitis CHepatitis AAntibodiesHepatitis B virusHepatitis B Surface AntigensHepatitisAntibody SpecificityAntibodies, ViralHepatitis C, ChronicHepatitis B, ChronicHepatitis, Viral, HumanHepatitis B AntibodiesHepatitis A virusHepatitis B VaccinesAntibodies, MonoclonalAntibodies, BacterialHepatitis, ChronicHepatitis B Core AntigensHepatitis A VaccinesHepacivirusHepatitis C AntibodiesHepatitis AntibodiesHepatitis B e AntigensHepatitis B AntigensAntibody FormationAntibodies, NeutralizingHepatitis EHepatitis E virusHepatitis A AntibodiesHepatitis, AutoimmuneHepatitis, Viral, AnimalHepatitis A Virus, HumanHepatitis VirusesHepatitis Delta VirusHepatitis DHepatitis, AnimalAntibody AffinityViral Hepatitis VaccinesFluorescent Antibody TechniqueAntiviral AgentsAntibodies, Anti-IdiotypicBinding Sites, AntibodyEpitopesMolecular Sequence DataMurine hepatitis virusHepatovirusHepatitis C AntigensHIV AntibodiesRNA, ViralAntibodies, AntinuclearAntibodies, NeoplasmAntibodies, ProtozoanImmunoglobulin MCross ReactionsInterferon-alphaLiver CirrhosisHepatitis A AntigensAmino Acid SequenceHepatitis delta AntigensHepatitis AntigensLiverAutoantibodiesHepatitis, AlcoholicRibavirinDNA, ViralSeroepidemiologic StudiesHepatitis B Virus, DuckAlanine TransaminaseRecombinant ProteinsViral Nonstructural ProteinsNeutralization TestsCarcinoma, HepatocellularImmunoglobulin GBase SequenceCell LineAntibodies, FungalMice, Inbred BALB CHepatitis B Virus, WoodchuckLiver NeoplasmsAntigen-Antibody ReactionsVirus ReplicationAntigen-Antibody ComplexEnzyme-Linked Immunosorbent AssayAntibodies, BispecificViral Core ProteinsPolyethylene GlycolsSingle-Chain AntibodiesGenotypeAntibodies, BlockingLamivudineImmunoglobulin Fab FragmentsImmunoenzyme TechniquesHepatitis D, ChronicVaccinationAntigens, ViralViral Envelope ProteinsImmunizationAntibodies, HeterophileFluorescent Antibody Technique, Indirect

Outbreak of hepatitis A in Korean military personnel. (73/165)

This report describes a hepatitis A outbreak among Korean military personnel. Each case of hepatitis A in this outbreak was defined as a person who had symptoms compatible with acute viral hepatitis A and had positive HAV IgM between May 2 and August 14, 2007 in Inje district, Gangwon, Korea. We tested 70 cases with symptoms for HAV IgM, and 67 cases showed positive results. They included 4 sergeants, 1 officer and 62 privates. A positive result for HAV IgG among asymptomatic military personnel was seen in 11.8% of cases. This epidemic occurred after a heavy rainfall in the military compound area where drinking water was supplied by the stream water. After the outbreak, the supply of drinking water was switched to a public water system. All of 178 military personnel who had no HAV IgG were vaccinated on July 26, 2007. The outbreak was resolved after the control measures were implemented.  (+info)

Age-specific seroprevalence of hepatitis A in Antananarivo (Madagascar). (74/165)

 (+info)

Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. (75/165)

 (+info)

Hepatitis A virus subgenotypes dissemination during a community outbreak in a surrounding region of Rio de Janeiro. (76/165)

 (+info)

Acute hepatitis A in a pregnant woman at delivery. (77/165)

 (+info)

Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults. (78/165)

 (+info)

High prevalence of hepatitis A virus antibody among Bangladeshi children and young adults warrants pre-immunization screening of antibody in HAV vaccination strategy. (79/165)

Serum samples from 465 subjects aged between 1 and 25 years were tested for antibody against hepatitis A virus (HAV) [anti-HAV IgG and IgM] to determine the seroprevalence of HAV antibody and do a cost-benefit analysis for decision making about vaccination against HAV among the general population of Bangladesh. A high prevalence of anti-HAV (74.8%) was observed in the study population; the whole study population was found positive for anti-HAV by the age of 25 years. On performing the cost-benefit analysis, it was found that the cost for vaccination with screening for anti-HAV was almost three times cheaper than vaccination without screening. Thus, in the present socioeconomic condition of Bangladesh, a policy based on screening for HAV antibody before vaccination is recommended.  (+info)

Immunogenicity and safety of live attenuated hepatitis A vaccine: a multicentric study. (80/165)

OBJECTIVE: To evaluate immunogenicity and tolerability of single dose live attenuated injectable hepatitis A vaccine in four metropolitan cities of India. METHODS: Live attenuated hepatitis A vaccine was administered to 505 children aged 18 to 60 months in four centers across India. Immunogenicity of the vaccine was assessed by estimation of anti-HAV antibody titer at 6 weeks and 6 months following administration of the vaccine. Safety evaluation of the vaccine was also done during the visits. RESULTS: At 6 weeks, 480 subjects (95%) came for the follow-up and 411 (81.4%) subjects reported at the end of 6 months. The geometric mean titer (GMT) of anti-HAV antibody of the subjects who did not have the seroprotective titer at the baseline were assessed at 6 weeks and 6 months which was 81.04 mIU/ml and 150.66 mIU/ml respectively. At 6 weeks, 95.1 % seroconverted and at the end of 6 months, 97.9 % had seroconverted. Both solicited and unsolicited vaccine-induced local and systemic adverse events were insignificant at all the centers, except swelling and induration in a few. CONCLUSION: Live attenuated injectable hepatitis A vaccine was immunogenic and tolerable with minimal reactogenecity, in this study of single dose schedule. Safety profile was also satisfactory in the study population.  (+info)